2025
Discover the inspiring journey of Sartorius BIA Separations, a biotech innovator that transformed challenges into triumphs, becoming a global leader in purification technologies for advanced therapies. As Aleš Štrancar, the founder, reflects, “We knew from the beginning that it would take 10–15 years to truly build the company, but we also expected the gene therapy market to grow. To survive, we turned to vaccines and novel therapies as well.”
Sartorius BIA Separations, a pioneering biotech company, has emerged as a global leader in the purification of viral vectors and biomolecules, essential for advanced therapies such as CAR-T and CRISPR-based treatments.
Founded in 1998 by Aleš Štrancar, the company has navigated a turbulent journey marked by financial challenges and strategic relocations. Despite setbacks, including a near-collapse in 2015, BIA Separations successfully restructured and was acquired by Sartorius in 2020 for over 360 million euros.
Today, Sartorius BIA Separations is renowned for its rapid development of purification technologies tailored to new therapies, impacting patient safety and advancing the biotechnology sector. With a strong presence in the United States and growing interest in Asia, the company is poised to capture significant opportunities in the global market.
For a detailed account of Sartorius BIA Separations’ remarkable journey and future prospects, read the full article in Entrepreneur Magazine’s November 2025 issue.
